CK2 Inhibitors – New CK2 Kinase Inhibitors for antineoplastic drugs and diagnostics
Beside cardiovascular diseases, malignant tumours take
the second place in cause of human death. Neoplastic diseases are indicated by a high cell proliferation. The inhibition of this cell proliferation by an active agent in a medicament is a worldwide accepted approach for tumour therapy. Protein kinase CK2 belongs together with others to the group of second-messenger independent kinases. Despite of unambiguous references for the involvement of CK2 in malignant transformation, tumour origin and progression, there are only a few effective inhibitors for this enzyme on-hand. This invention provides access to a novel class of potent human CK2 kinase inhibitors. The disclosed compounds can be used as active ingredients e.g. for the treatment of neoplastic diseases. Further, the patent application discloses synthesis of the compounds with optimised product yield.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Simplified diagnosis of rare eye diseases
Uveitis experts provide an overview of an underestimated imaging technique. Uveitis is a rare inflammatory eye disease. Posterior and panuveitis in particular are associated with a poor prognosis and a…
Targeted use of enfortumab vedotin for the treatment of advanced urothelial carcinoma
New study identifies NECTIN4 amplification as a promising biomarker – Under the leadership of PD Dr. Niklas Klümper, Assistant Physician at the Department of Urology at the University Hospital Bonn…
A novel universal light-based technique
…to control valley polarization in bulk materials. An international team of researchers reports in Nature a new method that achieves valley polarization in centrosymmetric bulk materials in a non-material-specific way…
